Restriction on the use of M-N-MA in Cosmetic Products
The European Commission has published the Commission Regulation (EU) 2022/135. This regulation amends the European Cosmetic Regulation, adding a new entry to Annex III. The use of Methyl-N-methylanthranilate (M-N-MA) in cosmetic products will be subject to restrictions.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate


Methyl-N-methylanthranilate (CAS number: 85-91-6), commonly called M-N-MA, is as fragrance ingredient used in several types of personal care and cosmetic products (e.g. fine fragrances, shampoos, soaps and others). It is also used in other types of products, like household cleaners and detergents.

At the moment, this ingredient is not currently included in the annexes of the European Cosmetics Regulation (No. 1223/2009), which means that its use is not restricted in cosmetic products placed in the European Union (EU).

The European Commission’s Scientific Committee on Consumer Safety (SCCS) has published opinions regarding the safety of M-N-MA use in cosmetic products.

In 2006, the SCCS concluded that M-N-MA was phototoxic, as demonstrated in in vitro and in vivo testing. Moreover, the SCCS stated that this ingredient should not be deliberately added to leave-on cosmetic products, because there is always the potential for light exposure.

Up to a maximum concentration of 0.1%, the use of M-N-MA in leave-on products (including deodorants and antiperspirants) was deemed as safe by the SCCS in 2011. But a risk could not be excluded for the use of this ingredient in sunscreen/sun care products or products (including fragrances) intended for use on areas exposed to light (especially face and neck).

Since M-N-MA is prone to nitrosation, so the SCCS indicated that it should not be used in combination with nitrosating agents and the nitrosamine content should be below 50 μg/kg.

In 2020, the SCCS issued a scientific advice on its last opinion on M-N-MA. The Scientific Committee stated that “Methyl-N-methylanthranilate should not be used in suncreen products and products marketed for exposure to natural/artificial UV light“. On other cosmetic products, SCCS considers M-N-MA safe when used up to 0.1% in leave-on preparations and up to 0.2% in rinse-off products.


The European Commission has published the Commission Regulation (EU) 2022/135, amending the European Cosmetic Regulation ((EC) No 1223/2009) as regards the use of Methyl-N-methylanthranilate in cosmetic products.

Following the SCCS opinions and scientific advice, the Commission considers that “there is a potential risk to human health arising from the use of M-N-MA in sunscreen products and products marketed for exposure to natural or artificial UV light and in other in other cosmetic products where the concentration of the substance is more than 0,1 % for leave-on products and 0,2 % for rinse-off products. Therefore, such use of M-N-MA should be prohibited.“.

Moreover, there is also a potential risk to human health arising from the use of this ingredient with nitrosating agents and the Commission states that such use of M-N-MA should be prohibited.

An entry will be added to Annex III (list of substances which cosmetic products must not contain except subject to the restrictions laid down) of the EU Cosmetic Regulation, restricting the use of M-N-MA.

Reasonable periods of time will be granted to the industry in order to make the necessary adjustments to product formulations and comply with new requirements and withdraw cosmetic products which do not comply with those requirements.

The European Cosmetics Regulation is considered one of the most complex in the world and being up to date can be a hard task. Critical Catalyst is here to help you. Feel free to contact us at


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Commission Regulation (EU) 2022/135 of 31 January 2022 amending Regulation (EC) No 1223/2009 of the European Parliament and of the Council as regards the use of Methyl-N-methylanthranilate in cosmetic products.


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »